Tilray, Inc. TLRY reported fourth-quarter losses at $2.14 per share, which does not compare to the 35-cent loss estimate. The company reported sales $46.936 million, which missed the analysts estimate of $55.92 million.
Tilray reported fourth-quarter total cannabis kilogram equivalents sold 15.039K kg and adjusted EBITDA loss of $35.3 million.
"Our full year results demonstrate strong sales growth momentum, which we expect to continue in 2020," said CEO Brendan Kennedy. "Like our peers, we have faced industry challenges, but we remain committed to driving long-term value for our shareholders. Tilray has a diversified business model comprised of global medical, Canada adult-use and hemp products which positions us well in the current volatile market environment."
Tilray's stock was down 10% in Monday's after-hours session after closing at $15.25 per share. The stock has a 52-week high of $82.81 and a 52-week low of $13.20.
Related Links:
Tilray, Aurora Cannabis Layoffs May Signal Industrywide Problem
Digesting What Cannabis 2.0 Means For The Industry: 'A Lot Of Opportunity'
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!